Before UCB made antibodies, it made ammonia. The Belgian company began in 1928 as Union Chimique Belge, an industrial concern that distilled ammonia from coal, produced chemicals and later sold films. There was a small pharmaceutical operation inside it, but nobody looking at the young conglomerate would have mistaken it for the focused biopharma business operating today. The route from one to the other was not a heroic overnight pivot. It was a long subtraction.
UCB built a pharmaceutical research center in the 1950s, found commercial success with the allergy medicine Zyrtec in the 1980s and followed with the epilepsy treatment Keppra in the 1990s. Then it chose its future. The company sold industrial activities, acquired British biotech Celltech in 2004 and Germany's Schwarz Pharma in 2006, and concentrated on diseases of the central nervous system and immune system. A sprawling Belgian manufacturer became a specialist drugmaker by deciding what it would stop being.
“Traditionally, science is connected to the patient. We want to connect patients to science.”Jean-Christophe Tellier, chief executive
That history matters because UCB's position is easy to misread. It is not a small biotech waiting for one clinical result. It is also not a diversified pharmaceutical giant selling into every common disease. UCB sits between those models: a publicly listed, global company with more than 9,000 employees in roughly 40 countries, but a deliberately narrow scientific field of view. Its scale funds specialist depth. Its focus keeps that scale from dissolving into dozens of unrelated franchises.
+26% year on year
around the world
on research & development
The job is not “make drugs.” It is remove a burden.
UCB works on severe conditions where biology is complicated and daily life can be ruled by uncertainty: whether a seizure will begin, whether inflamed skin will flare, whether muscles will weaken, whether a fracture will take away independence. Its customers form a chain rather than a single buyer. Patients use the medicines. Neurologists, rheumatologists, dermatologists and other specialists prescribe them. Hospitals and pharmacies deliver them. Insurers, governments and health systems decide how they are reimbursed.
The company makes money mainly from patented prescription-medicine sales. It also receives royalties, licensing payments and income from partnerships. In 2025, net sales were EUR 7.388 billion, alongside EUR 88 million in royalties and fees and EUR 265 million in other revenue. That money supports the expensive loop of drug discovery, clinical trials, regulatory submissions, manufacturing, market access and specialist sales. The cycle is unforgiving: each success must fund the candidates that will replace it when patents expire.
The current engine has five names. BIMZELX treats inflammatory diseases including plaque psoriasis, psoriatic arthritis, axial spondyloarthritis and hidradenitis suppurativa. It inhibits two related inflammatory signals, IL-17A and IL-17F, rather than one. RYSTIGGO and ZILBRYSQ attack generalized myasthenia gravis through different biological levers: the former targets the recycling of disease-causing antibodies; the latter inhibits part of the complement system. FINTEPLA treats seizures associated with rare childhood epilepsies. EVENITY, commercialized with Amgen and Astellas, builds bone in people with osteoporosis at high fracture risk.
Together, those five more than doubled sales to above EUR 3.3 billion in 2025. BIMZELX alone produced EUR 2.2 billion and had reached more than 116,000 patients by year-end. Older products still matter. CIMZIA generated nearly EUR 2 billion, while BRIVIACT produced EUR 758 million. But both illustrate the patent clock: CIMZIA has lost protection in the United States and Europe, and BRIVIACT's main U.S. and European exclusivity ended in 2026. Growth is not a trophy. It is replacement fuel.
A portfolio built around small, consequential moments
UCB's distinction is less about owning a disease category than about choosing precise populations within it. In rare epilepsy, a useful treatment may mean fewer seizures and a family day that can proceed without interruption. In myasthenia gravis, route and timing of administration can affect independence. In hidradenitis suppurativa, the problem is not only inflammation but years of delayed diagnosis, pain and stigma. UCB wraps medicine development with evidence gathering, access work and services such as UCBCares, which supports patients and healthcare professionals during treatment.
Patient and caregiver input helps define the outcome worth changing.
Antibodies, small molecules, data science and now cell therapy attack a defined mechanism.
Trials, approvals, manufacturing and reimbursement turn an asset into a treatment.
Some of the most revealing work happens beyond a product label. UCB and Morehouse School of Medicine use community health workers in Georgia to connect adults with epilepsy to neurology, primary care, behavioral health and social services. A Parkinson's health-equity board brought together 14 community leaders, patients, caregivers and trial experts to improve participation by underrepresented groups. With Stanford, UCB is studying digital signals around hidradenitis suppurativa; with the University of California, San Francisco, it is developing registry evidence. These programs do not erase the commercial logic. They show how a specialist builds knowledge that a generalist may not bother to collect.
UCB's moat is not a single molecule. It is the ability to repeat the same loop - narrow population, deep biology, specialist launch - before the patent clock runs out.
The next bets are more biological, not broader
UCB's 2026 dealmaking makes its ambitions unusually visible. In June it completed the acquisition of Candid Therapeutics for up to $2.2 billion. Candid's lead asset, cizutamig, is an investigational T-cell engager designed to direct T cells against disease-causing plasma cells and B cells. The phrase “immune reset” is the strategic promise: not merely dampening inflammation continuously, but removing the cells that sustain an autoimmune process. The asset is early, with multiple Phase 1 studies, so the science remains a bet rather than a product.
In April, UCB agreed to acquire Neurona Therapeutics for up to $1.15 billion. Its lead program, NRTX-1001, is an investigational neuronal cell therapy for drug-resistant temporal lobe epilepsy. The idea is to implant inhibitory neurons into the seizure-generating area of the brain and potentially restore local balance after a single administration. It is a long way from UCB's familiar tablets and injections, but close to its oldest modern expertise: epilepsy. Candid stretches the immunology platform; Neurona stretches the modality. Neither stretches the disease strategy.
Manufacturing is the third piece. UCB selected Gwinnett County, Georgia, for a planned 460,000-square-foot biologics campus on 79 acres. The company expects about 330 permanent jobs and describes a digital-first operation using automation, robotics and artificial intelligence. The location sits near UCB's U.S. headquarters in Smyrna and within reach of Georgia's university talent. A drug company can license a molecule. It cannot casually improvise dependable commercial supply. The factory is a physical hedge against growth.
Where UCB fits when the giants cast longer shadows
In immunology, UCB meets AbbVie, Johnson & Johnson, Eli Lilly, Novartis, Sanofi and other well-financed rivals. In neurology it encounters Biogen and specialized epilepsy companies. In myasthenia gravis, Argenx is a prominent alternative. Amgen is both competitor and partner. The market is crowded because chronic specialist medicines can produce durable revenue, and because the underlying diseases often support multiple mechanisms and treatment sequences.
UCB cannot out-broaden the largest pharmaceutical companies. It can try to out-focus them. Its dual inhibition with BIMZELX, paired but distinct approaches in myasthenia gravis, heritage in epilepsy, and attention to rare subpopulations provide differentiation. So does commercial familiarity with specialist doctors and reimbursement pathways. Yet there is no permanent comfort. Competitors improve, biosimilars arrive, regulators demand evidence and payers press prices. A pipeline candidate can fail after years of spending.
The useful lesson in UCB is not “be patient-centric”; almost every healthcare company says that. It is to turn focus into an operating constraint. Spend heavily in a few domains. Let patient experience influence trial design and service. Buy adjacent science rather than fashionable distance. Build capacity before it becomes comfortable. Measure the result in both revenue and people reached.
That discipline has produced a strong moment: 26% revenue growth in 2025, EUR 2.636 billion in adjusted EBITDA and more than 3.1 million patients reached. It has also raised the price of the next mistake. The five growth medicines must keep expanding while acquired technologies prove themselves and a large factory moves from rendering to production. UCB became more coherent by getting smaller in scope. Its next test is whether coherence survives becoming larger in ambition.